Market Overview

Goldman Downgrades Valeant, Sees 'Long Road' For Controversial Stock

Share:
Goldman Downgrades Valeant, Sees 'Long Road' For Controversial Stock
  • Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have declined 47.79 percent over the past month, hitting a low of $90.51 on October 21.
  • Goldman Sachs’ Gary Nachman has downgraded the rating on the company from Buy to Neutral, while lowering the price target from $180 to $122.
  • Nachman prefers to move to the sidelines until there is greater visibility on the measures management would take to rectify the damage to Valeant's reputation and grow its business in a challenging environment.

According to the Goldman Sachs report, "Given the events that have transpired very rapidly in recent weeks that have raised many questions about certain aspects of VRX’s business model, we have less confidence the market will reward the stock anytime soon without clarity as to the path forward."

Related Link: Valeant Ditches Philidor: Here's What It Really Means

Analyst Gary Nachman continues to believe that the company’s longer-term fundamentals warrant a “much higher” stock valuation, although the near to medium-term risk-reward profile appears less clear.

"We expect a much longer road than we previously thought for the dust to settle and for VRX to be able to regain enough investor confidence to attract a sufficient amount of new money into the stock," Nachman mentioned.

Nachman also expressed surprise regarding the company's decision to part ways with Philidor was not well received, suggesting investor concerns that Valeant's problems could possibly spill over to other business segments.

"We're more concerned about potential business risk for VRX with physicians, patients and customers as a result of all the recent developments," Nachman explained.

The EPS estimates for 4Q15 and 2016-2019 have been lowered, largely to reflect the impact of severing ties with Philidor.

Latest Ratings for VRX

DateFirmActionFromTo
Jun 2018DowngradesBuyHold
Jun 2018UpgradesEqual-WeightOverweight
May 2018UpgradesNeutralBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Gary Nachman Goldman Sachs PhilidorAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga

 

Related Articles (VRX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TXNJefferiesMaintains164.0
TCBIRBC CapitalMaintains59.0
ASMLRBC CapitalMaintains320.0
CLVSB of A SecuritiesMaintains10.0
FULCB of A SecuritiesMaintains22.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com